Celltrion says its tocilizumab biosimilar, Avtozma, is now commercially available to patients in the United States in subcutaneous formulation.

Avtozma (tocilizumab-anoh) is one of the first FDA-approved tocilizumab biosimilars in both subcutaneous (SC) and intravenous (IV) forms. Approvals for both formulations first came in January 2025.

Subcutaneous Formulation Follows Intravenous

The SC form of Avtozma covers several indications. These include rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA), and systematic juvenile idiopathic arthritis (SJIA).

“The introduction of Avtozma SC is a pivotal moment for Celltrion,” said Thomas Nusbickel, Celltrion USA Chief Commercial Officer. Nusbickel added it underscores Celltrion’s “dedication to delivering effective, accessible and user-friendly therapies for patients with chronic inflammatory diseases.”

In August 2025, the FDA approved Avtozma IV for an expanded indication, cytokine release syndrome (CRS). This brought Celltrion’s biosimilar in line with the IV formulation of the reference drug, Genentech’s Actemra IV.

Celltrion launched the IV form of Avtozma in the U.S. in October 2025.

Celltrion Adds Avtozma Flexibility

“By offering both IV and SC formulations, we aim to provide patients and healthcare professionals with greater flexibility,” Nusbickel said. He added that Celltrion continues “to broaden our immunology portfolio with therapies that address diverse inflammatory pathways.”

Celltrion said Avtozma SC is available in a 162 mg/0.9 mL solution, in either a single-dose prefilled syringe or autoinjector. As Nusbickel indicated, this allows patients flexibility and convenience to self-administer at home.

Additionally, Celltrion noted that its patient support program, Celltrion Connect, offers tailored support to both patients and caregivers. The program will be available for Avtozma for injection training, reimbursement assistance, and educational resources, among other services.